North America Lung Cancer Diagnostic Market Report

North America Lung Cancer Diagnostic Market Report, By Cancer Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), Diagnostic Tests (Biomarkers Test, Imaging Test, Biopsy), End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes) and Country- North America Market Share, Trend Analysis & Forecast , 2019 - 2028

Report Code : 10848 | Publish Date : Upcoming | Industry : Healthcare | Geography : North America


Lung cancer is having highest rate of deaths in case of cancers. The cigarette smoking and lung cancer has direct relation. The cigarette smoking is the leading cause of lung cancer, there is also increase in non-smoking related lung cancers. The genetic and environmental factors are also increasing susceptibility of cancer. The overall rate of survival in lung cancer is low. Lung cancer accounts for higher deaths than other cancers like prostate and colorectal cancers. Lung cancer treatment includes surgery, chemotherapy, radiotherapy and other. 

Market Dynamics- North America Lung Cancer Diagnostic Market

 The North America lung cancer diagnostic market is witnessing lucrative growth during forecast period 2021 to 2027. The rising death due to lung cancer is gaining attention of lung cancer diagnostic market. The dynamic factors such as rising geriatric population prone to smoking is propelling growth of North America lung cancer diagnostic market. The reimbursements and growing health insurance facilities are also refuelling the market growth. Additionally, arrival of nanomedicines to treat lung cancers is also driving the market growth. However, the high cost of diagnostic tests is hampering the growth of North America lung cancer diagnostic market. 

COVID-19 Impact on North America Lung Cancer Diagnostic Market

The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the lung cancer diagnostic market. In addition, complete analysis of changes on lung cancer diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines. 


North America Lung Cancer Diagnostic Market- Segmental Overview

The North America lung cancer diagnostic market is bifurcated into cancer type, diagnostic test, end user and country. 

North America Lung Cancer Diagnostic Market by Cancer Type 

Cancer type such as small cell lung cancer and non-small cell lung cancer is comprised in the North America lung cancer diagnostic market. In which small cell lung cancer is also contributing in the market growth. The small cell lung cancer is fast growing types of lung cancer. It is aggressive form of lung cancer which affect smokers mostly. It starts usually in bronchi (breathing tubes) and grows rapidly and creates large tumours along with spreading throughout the body. 

North America Lung Cancer Diagnosis Market by Diagnostic Test

Diagnostic test such as biomarkers test, imaging test, biopsy and other test are comprised in the North America lung cancer diagnosis market. The biomarkers test is sub-categorised into the CA test, HER2 Test, ALK Test, Angiogenesis Inhibitors, KRAS mutation test. Likewise, Imaging test is also sub-segmented into computed tomography scan, positron emission tomography scan and chest x-ray. The biopsy sub-segmented into needle biopsy, bronchoscopy biopsy and open biopsy. The imaging test is also contributing to the growth of North America lung cancer diagnostic market. The rising focus on early diagnosis is propelling growth of North America lung cancer diagnosis market. The increasing population of early smokers is also boosting growth of lung cancer diagnosis market. 

North America Lung Cancer Diagnosis Market by End Users

End user such as hospital assisted labs, independent diagnostic laboratories and cancer research centres are comprised in the North America lung cancer diagnosis market. In which independent diagnosis laboratories is also contributing to the growth of North America lung cancer diagnosis market. The growing prevalence of lung cancer is propelling growth of North America lung cancer diagnosis market.  The rising awareness regarding early diagnosis is also boosting growth of North America lung cancer diagnosis market. 

North America Lung Cancer Diagnosis Market by Country

The North America lung cancer diagnosis market is studied for key countries such as United States, Mexico and Canada. In which United States is anticipated to dominate the market in 2020. The rising research and development activities is propelling growth of North America lung cancer diagnosis market. The growing elderly population prone to smoking is also boosting growth of North America lung cancer diagnosis market. The rising awareness regarding diagnosis is also refuelling growth of North America lung cancer diagnosis is also driving growth of North America lung cancer diagnosis market. 

Key Players in Lung Cancer Diagnostic Market

The major key players operating in the lung cancer diagnostic market are Illumina Inc., Abbott, Thermo Fisher Scientific Inc., Qiagen, Quest Diagnostics Incorporated, Neogenomics, Nanostring Technologies Inc, Myriad Genetics Inc, Roche Holding Ag, Danaher, Agilent Technologies, Astrazeneca, Sanofi, Janssen Pharmaceuticals, Biomérieux Sa, Ge Healthcare, Hologic, Koninklijke Philips N.V, Biotheranostics and Exact Sciences among others. 

Key Developments in Lung Cancer Diagnostic Market

  • March 2021 Agilent Technologies Inc., entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions.
  • March 2020, Thermo Fisher Scientific entered into a partnership with Janssen Biotech, a part of Johnson & Johnson to develop lung cancer companion diagnostic.
  • July 2020, AnchorDx, a leading biotechnology company developing novel NGS-based early cancer detection and disease monitoring tests, entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a lung cancer study.
  • June 2019, Roche, launched in-vitro lung cancer diagnostic test VENTANA ROS1 (SP384) to target ROS1 positive lung cancer.

The report analyses the lung cancer diagnostic market based on cancer type, diagnostic test, end user and country. Various types of lung cancers covered in the lung cancer diagnostic market are small cell lung cancer and non-small cell lung cancers. By diagnostic test, the market is segmented into the biomarkers test, imaging test, biopsy and others. Based on end users, the market is segmented into the hospital associated labs, independent diagnostic laboratories and cancer research institutes. The report also imparts the impact of COVID-19 on the lung cancer diagnostic market and it founds that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines. The report also analyses the major key players operating in the market. 

Why to buy this report

  • The report offers changing market dynamics in the lung cancer diagnostic markets industry, presenting historical, current and projected market size in terms of value (USD Million)
  • The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of the lung cancer diagnostic market
  • It presents a comprehensive assessment of countries exhibiting promising growth, potential and niche segments and a neutral perspective of the lung cancer diagnostic market
  • The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of lung cancer diagnostic market